Vericel ( (VCEL) ) just unveiled an update.
Vericel Corporation anticipates minimal impact from the recent U.S. government tariffs on foreign goods, as its operations and revenue are entirely U.S.-based. The company expects that current and future tariffs will have an insignificant effect on its cost of goods sold and gross margin due to its reliance on domestic suppliers and significant safety stock of materials.
Spark’s Take on VCEL Stock
According to Spark, TipRanks’ AI Analyst, VCEL is a Neutral.
Vericel Corporation’s stock score reflects strong financial performance and positive earnings call sentiment, indicating a solid growth trajectory. However, technical analysis shows bearish signals, and the valuation appears stretched with a high P/E ratio. While the company demonstrates a robust operational outlook, potential investors should be cautious about the current stock price level and market trends.
To see Spark’s full report on VCEL stock, click here.
More about Vericel
Vericel Corporation operates in the biopharmaceutical industry, focusing on the development and commercialization of advanced cell therapies. Its primary products include MACI®, a treatment for cartilage defects, and Epicel®, a skin replacement therapy. The company primarily serves the U.S. market, with all operations and revenue derived domestically.
YTD Price Performance: -25.15%
Average Trading Volume: 455,937
Technical Sentiment Signal: Buy
Current Market Cap: $2.07B
See more data about VCEL stock on TipRanks’ Stock Analysis page.